BioniCare Medical Technologies to Present at Medtech Insight's ``Investment In Innovation'' Conference.Business Editors/Health/Medical Writers Medtech Insight 2004 In3 San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden Conference SAN FRANCISCO--(BUSINESS WIRE)--June 7, 2004 BioniCare Medical Technologies, Inc., a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , will be presenting on June 9 at 10:30 am (PST PST Paroxysmal supraventricular tachycardia, see there ) at Medtech Insight's Prestigious "Investment In Innovation" Event, taking place June 8-9, 2004 at the Palace Hotel in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . Thomas Zizic, M.D., President and Chief Executive Officer, and Gerald W. Faust, Ph.D., Chairman of the Board, both of BioniCare will give overviews of the company, its innovative platform technology and its first product, the BioniCare(R) Model BIO-1000(TM) System. The Model BIO-1000 System is the first and only non-invasive, non-drug option cleared for marketing by the U.S. Food and Drug Administration for the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. (OA) of the knee. The System is indicated for use as an adjunctive therapy adjunctive therapy Medtalk A therapeutic maneuver(s) with an ancillary role in treating a disease by ↓ M&M, but not part of the immediate therapy required to stabilize the Pt. Cf Adjuvant therapy. in reducing the level of pain and associated symptoms associated with OA of the knee, and for overall improvement of the knee as assessed by the physicians' global evaluation. The BIO-1000 System incorporates a soft Velcro wrap around the knee along with a signal generator A signal generator, also known variously as a test signal generator, function generator, tone generator, arbitrary waveform generator, or frequency generator which delivers a proprietary electrical stimulus that reduces pain and improves function in the treated arthritic joint. Twenty million Americans suffer from OA of the knee and more than six million remain symptomatic despite drug therapy. Currently, more than 100 medical centers in the U.S. are prescribing the Model BIO-1000(TM) System. Since its marketing launch in November 2003, the company has noted a growing acceptance of the System among physicians, patients and third-party payors. In March, BioniCare presented data suggesting the BIO-1000(TM) System can defer total knee replacement by up to four years in patients with moderate to severe OA. The company also recently acquired an option for the development of Gene Regulation technology (RGR RGR Roger RGR Rangers (US DoD) RGR Relative Growth Rate RGR Royal Gurkha Rifles (a British regiment) RGR Rassemblement des Gauches Républicaines ). RGR involves the use of electrodes on the skin to deliver specific electrical signals that, in experiments, remotely regulate the genes in cartilage cells. BioniCare Medical Technologies, Inc. develops and markets medical devices to meet the growing needs of more than 70 million Americans who suffer from the painful complications of arthritis. Through the application of its patented technology, BioniCare is committed to the development of safe and effective treatment alternatives to significantly improve the quality of patients' lives, and extend those benefits to a broader range of therapeutic indications. The BioniCare(R) BIO-1000(TM) System has also been cleared for marketing by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. of the hand and the commercial version of this product is expected to be on the market in 2005. BioniCare Medical Technologies, Inc. is based in Sparks, MD, with a satellite office in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA. For more information about the company and the benefits of the BIO-1000 System, please visit www.bionicare.com. About Medtech Insight Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the San Francisco conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail in3@medtechinsight.com, or visit http://www.medtechinsight.com/in3-11.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion